SAVA - NASDAQ
Cassava Sciences, Inc.
$1.96
-6.5%Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
At a Glance
Live SnapshotCassava Sciences, Inc. Management Team
Ms. Freda Nassif
Chief Business Officer & Chief Commercial Officer
Jaren Landen
Chief Clinical Development Officer
Mr. Richard Jon Barry
Chief Executive Officer, President & Director
Compensation
$319,375
Mr. Eric J. Schoen
Chief Financial Officer
Compensation
$725,000
Mr. R. Christopher Cook J.D.
Chief Operating & Legal Officer
Compensation
$425,000
Mr. Jack Moore Ph.D.
Senior Vice President of Clinical Development
Dr. Angélique Bordey Ph.D.
Senior Vice President of Neuroscience
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Dr. George Thornton Ph.D.
Senior Vice President of Technology
Cassava Sciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $709K worth of SAVA shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
258.7K
709.44K
0
0.00
+709K
+$709K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Barry Richard
Director, Officer: President & Ceo
$645K
Cook Robert Christopher
Officer: Chief Operating & Legal Office
$40K
Anderson Robert Eugene Jr
Director
$25K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $709K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
SAVA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | May 23, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 26, 2024 | May 09, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 27, 2023 | March 27, 2023 | ||
DEF 14A DEF 14A 2021 N/A | March 24, 2022 | December 31, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 31, 2021 | December 31, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | March 26, 2020 | March 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 29, 2019 | March 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 27, 2018 | March 26, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 21, 2017 | March 20, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 14, 2016 | April 13, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.